Identification of Recurrent Activating HER2 mutations in Primary Canine pulmonary Adenocarcinoma.

role of overexpression in lung cancer development in conjunction with erb-B-3 overexpression

value of this tumor marker regarding relapse, metastasis and death in resectable non-small cell lung cancer

Overexpression of HER2 is associated with recurrent non-small cell lung cancer

COX-2 up-regulates VEGF-C and promotes lymphangiogenesis in human lung adenocarcinoma via the EP(1)/Src/HER-2/Neu signaling pathway.

C-erbB-2 gene may be an important regulating gene in the coal miners with pneumoconiosis complicated by pulmonary cancer, and as a reference index to determine lymph node metastasis and prognosis.

serum epidermal growth factor receptor and HER2 have roles in response of advanced non-small cell lung cancer to chemotherapy

In operable non-small lung cell cancers, there may be different relationship of this protein with paatient outcome.

HER-2/neu and p53 may have a role in chemoresistance in patients with non-small cell lung cancer

The lack of gene amplification and robust HER-2/neu protein expression in small cell lung carcinoma (SCLC) tumour cells does not suggest a prominent role for the HER-2/neu gene in SCLC tumour progression.

These results suggest a relevant role for STAT5 and Bcl-xL as apoptosis-regulatory proteins in the pathogenesis of lung cancer, and overexpression of both Neu and activated STAT3, could be related with the proliferation rate in lung carcinoma cells.

Findings suggest that the ERBB2 mutation is rare in Korean lung cancer patients.

study of EGFR, HER2, TP53& KRAS mutations of p14arf expression of non-small cell lung cancers in relation to smoking

p53 and Ki-67, but not bcl-2, cyclin D1 or HER-2 may have roles in the process of tumor genesis in non-small cell lung carcinoma

Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer cells to trastuzumab and epirubicin.

PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancer cells.

All cases were wild-type for HER2. mutations of EGFR and K-ras genes represent an early event in lung adenocarcinomagenesis, and AAH convincingly seems to be a precursor lesion in a subset of cases of adenocarcinoma.

The protein product of the ERBB2 oncogene is overexpressed in 33.3% of small cell lung carcinomas and is associated with the presence of disseminated disease

findings indicate that serum HER2/neu levels are clinically valuable in monitoring metastatic breast cancer and non-small cell lung cancer patients.

polymorphisms of the HER-2 gene are associated with an increased susceptibility to lung cancer in females, non-smokers and non-drinkers subgroups in the Korean population

These data provided direct evidence that HER2/neu signaling is essential for tumorigenicity of non-small cell lung cancer cells

Non-small cell lung carcinoma brain metastases have some significant differences in HER family receptor-related abnormalities from primary lung tumors.

Nuclear Y-box binding protein-1 is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.

EGFR mutation combined with HER2/3 expression is a significant predictor for gefitinib efficacy on Chinese patients with advanced non-small cell lung cancer.

Overexpression of c-erbB-2 is associated with lung cancer.

Combining CEA with Cyfra 21-1 analysis of malignant pleural effusion increases diagnostic sensitivity of lung adenocarcinomato nearly 100%

Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors demonstrated antiangiogenic/antitumor effects in a lung cancer model.

Analysis revealed an association between HER2 protein expression and gene amplification in breast carcinoma. 14% of colon carcinomas, 2% of prostate carcinoma, 4% of lung carcinomas and 16% ovarian carcinomas revealed gene amplification.

High HER2 gene copy number in tumor epithelial cells is associated with non-small cell lung cancer.

mutations in ERBB2 is associated with adenocarcinoma of the lung.

meta-analysis suggests that HER2 overexpression is a poor prognostic factor in lung cancer

gene mutationa are not associated with the prognosis of patients with lung cancers

The expression of leptin, OB-Rb and HER-2 was significantly higher in non-small-cell lung cancer (NSCLC) tissues than in normal lung tissues. The expression of leptin is an independent prognostic factor for NSCLC.

Cinical study indicates that co-overexpression of Her2 with GEP100 in primary lung adenocarcinomas of patients is correlated with the presence of their node-metastasis with a statistical significance.

HER2 mutations in lung adenocarcinoma predominantly occurred in women and never smokers.

HER2 seems to be a valid therapeutic target of EGFR inhibitors in HER2-addicted lung carcinomas

analysis of HER2 overexpression in non-small cell lung cancer

mutations in the kinase domain of HER2 is associated with treatment response in lung adenocarcinoma.

HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2.

High-level ERBB2 amplification occurs in a small fraction of lung cancers with a strong propensity to high-grade adenocarcinomas.

These results implicate HER2 as a novel protein involved in the sensitivity or resistance of EGFR-mutant lung cancer

antierbB2 scFvFcIL2 fusion protein significantly delayed HER2 overexpression of nonsmall cell lung cancer (Calu3) in human nonsmall cell lung cancer xenografts in nude mice

HER2 exon 20 mutation is associated with non-small-cell lung cancer.

High HER2 expression is associated with lung adenocarcinoma-associated cytologically negative pleural effusions.

This study of patients presenting with HER2-mutated non-small-cell lung cancer, were found to be mainly female, nonsmokers, and exclusively suffering from adenocarcinoma subtype disease.

HER2 mutation was present in one male, non-smoking patient with low differentiated adenocarcinoma (0.67% of all patients with brain metastases from Non-small cell lung cancer and 1.5% of patients with adenocarcinoma).

HER2 receptor expression is detectable by immunohistochemistry in approximately 20% of non-small cell lung cancers and in 2% of NSCLC using gene amplification by FISH. HER2 is activated by axon 20 in frame insertion mutations in 2% of lung adenocarcinomas

Although up to 30% of non-small-cell lung cancer cases display HER2 overexpression, amplification or mutation, the prognostic significance of HER2 dysregulation remains undefined

Findings strongly suggest that mutations in the transmembrane domain of HER2 may be oncogenic, causing hereditary and sporadic lung adenocarcinomas.

Data indicate that responses were noted in patients with HER2-amplified breast cancer resistant to trastuzumab, HER2-mutant non-small-cell lung cancer, and tumor types without identified mutations in the HER-PI3K-mTOR pathway.

the study showed a significant association between low pleural glucose level and overexpression of HER2 in lung cancer.

HER2 protein overexpression, gene amplification, and gene mutations appeared to be uncommon in lung adenocarcinoma.

Neurotensin and its receptor NTSR1 causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung adenocarcinomas, confirming responsiveness to erlotinib.

The content of HER-2 protein and amplification of HER2 and CEP17 correlated with the clinical morphological parameters of patients with nonsmall cell lung cancer.

expression of HER2 and pAKT define a population of patients with stage IV pulmonary adenocarcinoma with a distinct disease course.

Human epidermal growth factor receptor 2 (HER2)-activating mutations are present in 1% to 2% of lung adenocarcinomas, with predominance in never smokers, association with gene amplification and overexpression

Data show that proto-oncogene protein HER-2 is directly regulated by microRNAs miR-125a and miR-125b in small cell lung cancer (SCLC).

HER2 mutation is associated with lung cancers.

In non-small cell lung cancer there is an elevated HER2 protein level and, well less frequently, altered activity in the HER2 gene.

Given the high prevalence of lung cancer and the availability of targeted therapy, Chinese lung ADC patients without EGFR and KRAS mutations are recommended for HER2 and BRAF mutations detection, especially for those never smokers

SNP in HER2 codon 655 and investigation of HER2 and HER3 expression could be helpful to outline the prognosis for patients with lung adenocarcinoma.

Her2 mutation is associated with response to therapy in lung cancer.

HER2 genetic alteration in non-small cell lung cancer is associated with the treatment outcome with tyrosine kinase inhibitors. [review]

Increased expression of HER2 was linked to poor outcome in lung cancer patients.

HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target. HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.

ERBB2 Exon 20 Insertion-mutation is associated with response to chemotherapy in lung Adenocarcinomas.

High HER2 expression is associated with non-small cell lung cancer.

HER2 insertion could define a distinct subset of NSCLC, which had a higher prevalence among females, nonsmokers, and adenocarcinoma. HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.

or patients with non-small cell lung cancer with a EGFR mutation and an anaplastic lymphoma kinase mutation(ALK) with brain metastases, several agents have shown intracranial activity. Lapatinib has been tested for patients with brain metastases from breast cancer harboring a HER2 mutation. molecular targeted therapies have shown efficacy in BRAF-positive melanoma brain metastasis

Review of the role of HER-2 mutation in non-small cell lung carcinoma development, diagnosis, and treatment.

c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis.

High HER2 expression is associated with lung cancer.

HER2 Transmembrane Domain mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers that are associated with lung Adenocarcinoma.

HER2 mutation is associated with response to chemotherapy in lung adenocarcinoma.

Our study suggests that HER2 overexpression or amplification is a poor prognostic factor in lung adenocarcinoma, although the frequency of such events is low.

the present study suggests that HER2 has an important role in the regulation of the cancer stem-like cells phenotype in ALK translocated lung cancers that is mainly orchestrated by HER2/HER3 heterodimers.

ERBB2 amplification is driving resistance to erlotinib in lung adenocarcinoma.

The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study.

T-DM1 showed a signal of activity in patients with HER2-overexpressing (IHC 3+) advanced non-small cell lung cancer

Pyrotinib showed activity against non-small-cell lung cancer with HER2 exon 20 mutations in both patient-derived organoids and a patient-derived xenografts model. In the clinical trial, pyrotinib showed promising efficacy

EGFR/ERBB2 germline mutations were found to be rare in Chinese lung cancer patients with more diversity other than the previously reported EGFR-T790M, with EGFR-K757R being the most common EGFR germline mutation.

Patients with an HER2-aberrant tumor lung cancer occurred more frequently in females and had a significantly worse prognosis. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n = 15).

Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell lung cancer.

Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma.

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.

An ErbB2 splice variant lacking exon 16 drives lung carcinoma.

Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant lung cancers.

Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis

analysis of lung tumors treated with BIBW2992 and rapamycin combination in HER2(YVMA) transgenic mice revealed decreased phosphorylation levels for proteins in both upstream and downstream arms of MAPK and Akt/mTOR signaling axes

Metastasis of ErbB-2-dependent murine mammary cancers in vivo required Plexin B1. Overexpression of ErbB-2 stimulated Rho signaling & lung metastasis.